Last reviewed · How we verify

NCT05588076

Endometrial Lesions Predictions

Status unknown Last updated 20 October 2022
What this trial tests

trial testing no intervention in Endometrial Neoplasms in 900 participants. Status unknown.

Timeline
1 October 2021
Primary endpoint
1 October 2022
1 December 2022

Quick facts

Lead sponsorBeijing Friendship Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment900
Start date1 October 2021
Primary completion1 October 2022
Estimated completion1 December 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Friendship Hospital

Who can join

Adults 18 to 60, female only, with Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the risk factors of endometrial lesions in patients with abnormal uterine bleeding and establish prediction models which can discriminate between different endometrial etiologies of abnormal uterine bleeding(AUB).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Endometrial Neoplasms

Currently open trials in the same condition.

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05588076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing